The Multi-Arm GlioblastoMa Australasia (MAGMA) Trial is a platform trial that will aim to assess a number of options in standard of care for the management of glioblastoma. Initial questions of interest are: QUESTION 1 whether or not to give daily temozolomide as soon as possible after surgery prior to chemoradiotherapy (CRT) and QUESTION 2: whether to give 6 cycles of temozolomide after CRT, or continue monthly treatment until disease progression.

See full ANZCTR details for MAGMA >

 

Trial Summary:

A multi-arm multi-stage, multi-centre, phase III (MAMS) platform trial that aims to assess hypotheses against a common standard-of-care control arm for the management of people with glioblastoma. Initial questions of interest are: QUESTION 1: whether to give metronomic temozolomide as soon as possible following surgery prior to chemoradiotherapy; and QUESTION 2: whether to give a plan for 6 cycles of standard schedule adjuvant temozolomide chemotherapy (5/28 day cycles) after chemoradiotherapy, or continue temozolomide until progression.

Supported by:

Australian Brain Cancer Mission, including Cancer Australia, Carries Beanies for Brain Cancer, and the Mark Hughes Foundation, through the MRFF.

Eligibility:

Adults, aged 18 years and older, with newly diagnosed histologically confirmed grade IV malignant glioblastoma.

Registration ID:

ACTRN12620000048987

Participation:

Australia

Australian Lead Group:

COGNO

Status:

Recruiting

Activation Date:

09/2020

Chairs:

A/Prof Craig Gedye

Contact:

magma.study@sydney.edu.au